Objective To investigate the clinical effect of dapagliflozin+repaglinide+insulin glargine in patients with type 2 diabetes mellitus.Methods A total of 94 patients with type 2 diabetes mellitus admitted to Zhangdian District Traditional Chinese Medicine Hospital in Zibo from March 2023 to March 2024 were selected as the research objects.According to different treatment methods,they were divided into general group and inquiry group,with 47 cases in each group.The general group was treated with repaglinide+insulin glargine,and the inquiry group was treated with dapagliflozin on the basis of the general group.The blood glucose indexes,blood glucose fluctuation indexes,total ef-fective rate of treatment efficiency and incidence of adverse reactions were compared between the two groups.Results After treatment,the levels of fasting plasma glucose,2-hour postprandial plasma glucose in both groups decreased,and those in the inquiry group were lower than the general group,the differences were statistically significant(all P<0.05).After treatment,the mean blood glucose and standard deviation of blood glucose levels in the two groups de-creased,and those in the inquiry group were lower than the general group,the differences were statistically significant(both P<0.05).The total effective rate of treatment in the inquiry group was 97.87%(46/47),which was higher than 82.98%(39/47)in the general group,and the difference was statistically significant(x2=6.021,P=0.014).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The com-bination of dapagliflozin+repaglinide+insulin glargine is more effective in the treatment of type 2 diabetes mellitus,which can regulate the fluctuation of blood glucose on the basis of reducing blood glucose,and does not increase the incidence of adverse events and promote the recovery of patients with type 2 diabetes mellitus.
维普
万方数据
